Johnson & Johnson (JNJ)
Develops prescription medicines and cardiovascular, surgical, orthopaedic and vision technologies.
$269.50
vs last close+0.03 (+0.01%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Oct 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21,351 | 21,395 | 21,383 | 22,447 | 22,471 | 22,520 | 21,893 | 23,743 | 23,993 | 24,564 | 24,062 | 25,310 |
| Cost of revenue | 6,606 | 6,798 | 6,511 | 6,869 | 6,963 | 7,128 | 7,357 | 7,628 | 7,303 | 7,968 | 8,106 | 8,051 |
| Gross profit | 14,745 | 14,597 | 14,872 | 15,578 | 15,508 | 15,392 | 14,536 | 16,115 | 16,690 | 16,596 | 15,956 | 17,259 |
| 8,547 | 9,990 | 8,599 | 8,921 | 10,230 | 11,551 | 8,237 | 9,305 | 9,594 | 11,005 | 9,561 | 10,085 | |
| Research & development | 3,447 | 4,480 | 3,542 | 3,440 | 4,952 | 5,298 | 3,225 | 3,516 | 3,672 | 4,252 | 3,527 | 3,653 |
| 5,100 | 5,510 | 5,057 | 5,481 | 5,278 | 6,253 | 5,012 | 5,789 | 5,922 | 6,753 | 6,034 | 6,432 | |
| General & administrative | 5,100 | 5,510 | 5,057 | 5,481 | 5,278 | 6,253 | 5,012 | 5,789 | 5,922 | 0 | 0 | 0 |
| Operating income | 6,198 | 4,607 | 6,273 | 6,657 | 5,278 | 3,841 | 6,299 | 6,810 | 7,096 | 5,591 | 6,395 | 7,174 |
| −981 | 219 | −2,559 | −909 | −1,940 | 46 | 7,332 | −319 | 397 | −625 | −405 | −427 | |
| Interest income | 374 | 363 | 364 | 395 | 292 | 281 | 332 | 260 | 227 | 237 | 229 | 219 |
| Interest expense | 192 | 151 | 155 | 270 | 193 | 137 | 204 | 308 | 245 | 214 | 272 | 281 |
| Other non-operating income | 789 | −370 | 2,404 | 639 | 1,747 | −183 | −7,536 | 11 | −415 | 411 | 133 | 146 |
| Income before tax | 5,217 | 4,826 | 3,714 | 5,748 | 3,338 | 3,887 | 13,631 | 6,491 | 7,493 | 4,966 | 5,990 | 6,747 |
| Income tax expense | 908 | 694 | 459 | 1,062 | 644 | 456 | 2,632 | 954 | 2,341 | −150 | 755 | 1,213 |
| Net income from continuing operations | 4,309 | 4,132 | 3,255 | 4,686 | 2,694 | 3,431 | 10,999 | 5,537 | 5,152 | 5,116 | 5,235 | 5,534 |
| Discontinued operations | 21,719 | −83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 26,028 | 4,049 | 3,255 | 4,686 | 2,694 | 3,431 | 10,999 | 5,537 | 5,152 | 5,116 | 5,235 | 5,534 |
| EPS, basic | $10.32 | $1.68 | $1.35 | $1.95 | $1.12 | $1.43 | $4.57 | $2.29 | $2.14 | $2.10 | $2.14 | $2.27 |
| EPS, diluted | $10.21 | $1.67 | $1.34 | $1.93 | $1.11 | $1.41 | $4.54 | $2.29 | $2.12 | $2.10 | $2.14 | $2.27 |
| Weighted average shares, basic | 2,523 | 2,407 | 2,408 | 2,407 | 2,407 | 2,407 | 2,406 | 2,419 | 2,429 | 2,429 | 2,445 | 2,440 |
| Weighted average shares, diluted | 2,550 | 2,431 | 2,430 | 2,422 | 2,428 | 2,427 | 2,424 | 2,419 | 2,429 | 2,439 | 2,445 | 2,440 |
| EBITDA | 7,238 | 6,820 | 5,684 | 7,800 | 5,377 | 5,920 | 15,607 | 8,742 | 9,288 | 7,191 | 8,266 | 8,987 |
| Depreciation & amortization | 1,829 | 1,843 | 1,815 | 1,782 | 1,846 | 1,896 | 1,772 | 1,943 | 1,777 | 2,011 | 2,004 | 1,959 |
| EBIT | 5,409 | 4,977 | 3,869 | 6,018 | 3,531 | 4,024 | 13,835 | 6,799 | 7,511 | 5,180 | 6,262 | 7,028 |